Calcium Channel Blockers: New Therapeutic Targets for Alzheimer's Disease

The Neuroscience Journal of Shefaye Khatam Pub Date : 2020-12-01 DOI:10.52547/shefa.9.1.1

H. Bozorgi, Hamed Darbanian

{"title":"Calcium Channel Blockers: New Therapeutic Targets for Alzheimer's Disease","authors":"H. Bozorgi, Hamed Darbanian","doi":"10.52547/shefa.9.1.1","DOIUrl":null,"url":null,"abstract":"1. Alzheimer Disease 2. Calcium Channel Blockers 3. Therapeuticse Introduction: Alzheimer’s disease (AD) is the mos t common type of dementia in the elderly. Memory impairment usually occurs gradually and progressively. AD has not only been associated with decreased cerebral acetylcholine concentration, oxidative s tress, and beta-amyloid protein deposition, but more recent s tudies have shown that neurodegeneration induced by dis turbance of the intracellular calcium homeos tasis is also involved in the pathophysiology of the disease. It has been reported that calcium channel blockers (CCBs) have beneficial effects in different models of memory impairment. Here, we review and discuss the effects of CCBs, especially N-types, as novel agents that have effects on memory deficits in animal models of AD. on contrary to the L-type calcium channels, which are presented in the other organs in addition to nerve cells, N-type calcium channels are commonly located on the neurons. The main advantage of N-type CCBs is their lower side effects than other CCBs. Conclusion: Targeting the N-type CCBs may contribute to the new s trategies for the treatment of AD. ABSTRACT Article Info:","PeriodicalId":22899,"journal":{"name":"The Neuroscience Journal of Shefaye Khatam","volume":"244 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Neuroscience Journal of Shefaye Khatam","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52547/shefa.9.1.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

1. Alzheimer Disease 2. Calcium Channel Blockers 3. Therapeuticse Introduction: Alzheimer’s disease (AD) is the mos t common type of dementia in the elderly. Memory impairment usually occurs gradually and progressively. AD has not only been associated with decreased cerebral acetylcholine concentration, oxidative s tress, and beta-amyloid protein deposition, but more recent s tudies have shown that neurodegeneration induced by dis turbance of the intracellular calcium homeos tasis is also involved in the pathophysiology of the disease. It has been reported that calcium channel blockers (CCBs) have beneficial effects in different models of memory impairment. Here, we review and discuss the effects of CCBs, especially N-types, as novel agents that have effects on memory deficits in animal models of AD. on contrary to the L-type calcium channels, which are presented in the other organs in addition to nerve cells, N-type calcium channels are commonly located on the neurons. The main advantage of N-type CCBs is their lower side effects than other CCBs. Conclusion: Targeting the N-type CCBs may contribute to the new s trategies for the treatment of AD. ABSTRACT Article Info:

查看原文本刊更多论文

钙通道阻滞剂:阿尔茨海默病的新治疗靶点

1. 2.老年痴呆症钙通道阻滞剂治疗方法介绍:阿尔茨海默病(AD)是老年痴呆症中最常见的类型。记忆障碍通常是逐渐发生的。阿尔茨海默病不仅与脑乙酰胆碱浓度降低、氧化应激和β -淀粉样蛋白沉积有关，而且最近的研究表明，由细胞内钙同质转运紊乱引起的神经退行性变也参与了该疾病的病理生理。据报道，钙通道阻滞剂(CCBs)对不同类型的记忆障碍有有益的作用。在此，我们回顾并讨论了CCBs，特别是n型CCBs作为对AD动物模型中记忆缺陷有影响的新型药物的作用。与l型钙通道存在于除神经细胞外的其他器官不同，n型钙通道通常位于神经元上。n型ccb的主要优点是其副作用比其他ccb低。结论:以n型CCBs为靶点，可能是治疗AD的新策略之一。摘要文章简介:

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

The Neuroscience Journal of Shefaye Khatam

自引率

0.00%

发文量